Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens

Obstetrics and Gynecology

Volumn 91, Issue 1, 1998, Pages 35-39

  Cushing, Kara L ^a,b   Weiss, Noel S ^a   Voigt, Lynda F ^a   McKnight, Barbara ^a   Beresford, Shirley A A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN;

ADULT; AGED; ARTICLE; BONE ATROPHY; CANCER RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; DATA ANALYSIS; ENDOMETRIUM CANCER; FEMALE; HIGH RISK POPULATION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL;

AGED; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; RISK FACTORS; SOCIAL CLASS; WASHINGTON;

EID: 0031962282     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(97)00577-2     Document Type: Article

References (16)

1. 1. Antunes CM, Stolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, et al. Endometrial cancer and estrogen use: Report of a large case-control study. N Engl J Med 1979;300:9-13.
2. 2. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349: 458-61.
3. 3. Green PK, Weiss NS, McKnight B, Voigt LF, Beresford SA. Risk of endometrial cancer following cessation of menopausal hormone use. Cancer Causes Control 1996;7:575-80.
4. 4. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-7.
5. 5. Paterson ME, Wade-Evans T, Sturdee DW, Thom MH, Studd JW. Endometrial disease after treatment with oestrogens and progestogens in the climacteric. BMJ 1980;280:822-4.
6. 6. Whitehead MI, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol 1990;75:59S-76S.
7. 7. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984;63:759-63.
8. 8. Weiss NS, Szekely DR, English DR, Schweid AI. Endometrial cancer in relation to patterns of menopausal estrogen use. JAMA 1979;242;261-4.
9. 9. Gray LA, Christopherson WM, Hoover RN. Estrogens and endometrial carcinoma. Obstet Gynecol 1977;49:385-9.
10. 10. Jick H, Watkins RN, Hunter JR, Dinan BJ, Madsen S, Rothman KJ, et al. Replacement estrogens and endometrial cancer. N Engl J Med 1979;300:218-22.
11. 11. Waksberg J. Sampling methods for random digit dialing. J Am Stat Assoc 1978;73:40-6.
12. 12. Herrington LJ, Weiss NS. Post-menopausal unopposed estrogens: Characteristics of use in relation to risk of endometrial carcinoma. Ann Epidemiol 1993;3:301-18.
13. 13. Gordon MD, Ireland K. Pathology of hyperplasia and carcinoma of the endometrium. Semin Oncol 1994;21:64-70.
14. 14. Stadel BV, Weiss NS. Characteristics of menopausal women: A survey of King and Pierce counties in Washington, 1973-1974. Am J Epidemiol 1975;102:209-16.
15. 15. Paganini-Hill A, Ross RK. Reliability of recall of drug usage and other health-related information. Am J Epidemiol 1982;116:114-22.
16. 16. Persson I, Bergkvist L, Adami H. Reliability of women's histories of climacteric oestrogen treatment assessed by prescription forms. Int J Epidemiol 1987;16:222-8.